Mostrando 10 resultados de: 10
Subtipo de publicación
Article(10)
Publisher
Clinical Cancer Research(3)
Breast Cancer: Basic and Clinical Research(2)
Cancer Biology and Therapy(2)
Cancer Management and Research(1)
Human Vaccines(1)
Área temáticas
Enfermedades(10)
Farmacología y terapéutica(8)
Ginecología, obstetricia, pediatría, geriatría(1)
Medicina y salud(1)
Origen
scopus(10)
1E10 anti-idiotype vaccine in non-small cell lung cancer: Experience in stage IIIb/IV patients
ArticleAbstract: Conventional treatment of non-small cell lung cancer (NSCLC) has apparently reached a plateau of effPalabras claves:Anti-idiotype antibody, Cancer Vaccines, Clinical study, immunotherapyAutores:Aguirre F., Alfonso S., Alonso D.F., Barroso M.C., Carmen Elena Viada, De La Torre A.V., Díaz R.M., Gabri M.R., Gómez R., Hernández A.M., Macías A.E., Pérez K., Pérez R., Rodríguez J., Santiesteban E.R., Suárez E., Toledo D., Vázquez A.M.Fuentes:scopusA Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients
ArticleAbstract: Purpose: EGFR is a well-validated target for patients with non-small cell lung cancer (NSCLC). CIMAvPalabras claves:Autores:Acosta S.C., Aguilera N., Alonso L., Amador R.M., Arzuaga L., Cala M., Carmen Elena Viada, Catala M., Crespo T., De La Torre A.V., Fleytas R., Flores Y.I., Futiel N., García Verdecia B., Lage Davila A., Luaces P.L.o., Marrero Miragaya M.A., Martínez O., Mazorra Z., Mendoza S., Neninger Vinageras E., Otero Y., Parra J., Pomares Y., Popa X., Reyes D., Rodríguez G., Rodríguez P.C., Romero G.N., Sabates T., Santiesteban E.R., Sierra P., Tania Crombet, Vello L.Fuentes:scopusA randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients
ArticleAbstract: Purpose: Racotumomab-alum is an anti-idiotype vaccine targeting the NeuGcGM3 tumor-associated gangliPalabras claves:Autores:Alfonso S., Areces F., Carmen Elena Viada, Cepeda M., Chong E., De La Torre A.V., Flores Y.I., García E., Gonzalez Z., Guerra P.P., Hernández A.M., Hernández M., Macías A.E., Mazorra Z., Mendoza I.C., Ortiz R.A., Pérez K., Pérez R., Santiesteban E.R., Tania Crombet, Toledo D., Valdes-Zayas A., Vázquez A.M.Fuentes:scopusActive immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: Report of a phase I trial
ArticleAbstract: 1E10 is an anti-idiotype murine monoclonal antibody (Ab2 MAb) specific to an Ab1 MAb which reacts wiPalabras claves:Anti-idiotype antibody, Cancer Vaccines, Clinical study, immunotherapyAutores:Alfonso A.M., Alonso D.F., Bárbara Wilkinson, Combet T., De La Torre A.V., Díaz A., Díaz R.M., Gabri M.R., Neninger Vinageras E., Pérez R., Rives R., Saurez G., Vázquez A.M.Fuentes:scopusEffect of vaccination with N-glycolyl GM3/VSSP vaccine by subcutaneous injection in patients with advanced cutaneous melanoma
ArticleAbstract: NeuGc-containing gangliosides have been described in melanoma cells and are an attractive target forPalabras claves:Clinical trial, Ganglioside, melanoma, N-glycolyl GM3, Therapeutic vaccineAutores:Ávila Y., Carmen Elena Viada, Carr A., Cepeda M., De La Torre A.V., Fernandez L.E., Gracia E., Hernandez J., Osorio M., Pérez K., Reigosa E., Rodríguez M., Saurez G.Fuentes:scopusEffective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine
ArticleAbstract: Purpose: Epidermal growth factor (EGF) might be a suitable immunotherapeutic target in non-small-celPalabras claves:Autores:Carmen Elena Viada, De La Torre A.V., García Verdecia B., González G., Lage Davila A., Leonard I., Martínez R., Mazorra Z., Neninger Vinageras E., Tania CrombetFuentes:scopusNGlycolylGM3/VSSP vaccine in metastatic breast cancer patients: Results of phase I/IIa clinical trial
ArticleAbstract: Patients treated with vaccines based on NGlycolil gangliosides have showed benefit in progression frPalabras claves:Clinical trial, Ganglioside, Metastatic breast cancer, NGcGM3, Therapeutic vaccineAutores:Arboláez M., Car A., Carmen Elena Viada, Cepeda M., De La Torre A.V., Fernandez L.E., García E., Guerra P.P., Hernandez J., Ortiz R.A., Pérez K., Toledo D.Fuentes:scopusImmunogenicity and safety of a NeuGcGM3 based cancer vaccine: Results from a controlled study in metastatic breast cancer patients
ArticleAbstract: Increased levels of NeuGc-containing gangliosides have been described in human breast cancer. A contPalabras claves:Breast Cancer, cancer vaccine, Clinical trial, Ganglioside, immunotherapy, NeuGcGM3, patientsAutores:Cardoso J., Carmen Elena Viada, Carr A., De La Torre A.V., Díaz R., Fernandez L.E., Macías A.E., Marinello P., Mazorra Z., Mulens V., O'Farrill M., Pérez R., Rodríguez R., Saurez G., Tania CrombetFuentes:scopusPhase II randomized controlled trial of an epidermal growth factor vaccine in advanced non-small-cell lung cancer
ArticleAbstract: Purpose: We show the result of a randomized phase II clinical trial with an epidermal growth factorPalabras claves:Autores:Abreu D.A., Bravo I., Brooks S.A., Carmen Elena Viada, Carrillo C.d.C., Dávila A.L., De La Torre A.V., Del Pino M.M., Dueñas M.G., Ferrer M.C., Marinello G.G., Ramos T.C., Rives R., Rodríguez M.O., Verdecia B.G., Vinageras E.N.Fuentes:scopusSuperior efficacy and safety of a nonemulsive variant of the NGcGM3/VSSP vaccine in advanced breast cancer patients
ArticleAbstract: NGcGM3 ganglioside is a tumor-specific antigen expressed in human breast tumors. The NGcGM3/VSSP vacPalabras claves:Breast Cancer, NGcGM3/VSSP vaccine, SurvivalAutores:Arencibia M., Cabrera L., Carmen Elena Viada, Cepeda M., De La Torre A.V., Domecq M., Durán Y., Durrutí D., Fernandez L.E., Hernández J.J., Hernández L., Mabel Álvarez, Moreno Y.G., Pérez K., Ruiz R., Sánchez J.L., Sánchez L., Santiesteban E.R., Valls A.R., Vega A.M.Fuentes:scopus